This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pulling the Plug on Achillion

NEW YORK ( TheStreet) -- As much as I love this business of financial writing, there is nothing that I love more than being right.

And I love telling you about it. But if you stay in the business long enough, you'll realize that every once in a while, a writer has to take it on the chin and admit that he was just flat-out wrong about a call.

While I've never expected to nail every prediction with pinpoint accuracy, I can't say I've ever blown a call to the extent of Achillion Pharmaceuticals (ACHN), a company that has now become a shell of itself, if not a complete disaster.

Now, if you know anything about the biotech industry, it's extremely volatile. But this is a sector that moves quickly in either direction on the prospects on new drug production and the approval of regulators like the Food and Drug Administration (FDA). So back in July, following the stock's 25% drop on news that Sovaprevir, the company's lead protease inhibitor for hepatitis C (HCV) had been put on hold by the FDA due to safety concerns, I called it a buying opportunity.

At the time, shares were trading around $6 after falling from well above $8.

Fast-forward three months later: shares have just made a new 52-week low of $2.87 as of Monday's trading. With a close of $3.02 Monday, essentially from the time that Achillion began its selloff in July, the stock has now lost 64%, including falling 53% since my buy recommendation. Before we go into why the company is getting hammered this time, let's revisit my buy thesis from July.

I'm not here to make any excuses because, clearly, I have no place to hide here. However, as I've noted, thick skin is required to be an investor in this sector. And to make any money at all (as the shorts are likely counting today), requires not only a significant amount of risk, but also an understanding of how these drugs come to market. It's not an easy process. In the July article, I said:

I don't disagree that Achillion brings considerably more risk than a much improved Abbott Labs (ABT) or a powerhouse like Johnson & Johnson (JNJ). But after this recent 25% decline, Achillion's stock has become a bit more interesting, if not significantly undervalued.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ACHN $8.58 0.00%
AAPL $126.44 0.00%
FB $87.28 0.00%
GOOG $523.40 0.00%
TSLA $280.02 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs